CNS Pharmaceuticals | Press Releases

Overview Financials & Filings Press Releases Events Corporate Governance Stock Information FAQS

Press Releases

Title

Date

05 December, 2024

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11 2024

25 November, 2024

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM WHO Grade IV After Failure of Standard First Line Therapy

18 November, 2024

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro Oncology SNO 2024

15 November, 2024

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

04 November, 2024

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment

01 November, 2024

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

23 October, 2024

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At The Market Under Nasdaq Rules

10 October, 2024

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment

There are no press releases that match the selected filters.

View More

Stay Updated

All Press Releases
All SEC Filings
End of Day Stock Data
Weekly

At least one type of alert must be selected.

An email address is required.

Your email alerts were set.

The following alerts could not be set: